Free Trial

Xencor (XNCR) Competitors

Xencor logo
$7.69 +0.17 (+2.26%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$7.69 0.00 (0.00%)
As of 05/22/2025 05:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

XNCR vs. MIRM, APLS, ARWR, VCEL, NAMS, GMTX, AAPG, BLTE, HRMY, and DNLI

Should you be buying Xencor stock or one of its competitors? The main competitors of Xencor include Mirum Pharmaceuticals (MIRM), Apellis Pharmaceuticals (APLS), Arrowhead Pharmaceuticals (ARWR), Vericel (VCEL), NewAmsterdam Pharma (NAMS), Gemini Therapeutics (GMTX), Ascentage Pharma Group International (AAPG), Belite Bio (BLTE), Harmony Biosciences (HRMY), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry.

Xencor vs.

Mirum Pharmaceuticals (NASDAQ:MIRM) and Xencor (NASDAQ:XNCR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Mirum Pharmaceuticals has a net margin of -31.69% compared to Xencor's net margin of -232.77%. Xencor's return on equity of -30.92% beat Mirum Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Mirum Pharmaceuticals-31.69% -41.22% -14.81%
Xencor -232.77%-30.92%-21.74%

Xencor received 373 more outperform votes than Mirum Pharmaceuticals when rated by MarketBeat users. However, 76.40% of users gave Mirum Pharmaceuticals an outperform vote while only 73.13% of users gave Xencor an outperform vote.

CompanyUnderperformOutperform
Mirum PharmaceuticalsOutperform Votes
136
76.40%
Underperform Votes
42
23.60%
XencorOutperform Votes
509
73.13%
Underperform Votes
187
26.87%

Mirum Pharmaceuticals has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Xencor has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500.

Mirum Pharmaceuticals currently has a consensus target price of $60.73, suggesting a potential upside of 37.86%. Xencor has a consensus target price of $29.50, suggesting a potential upside of 283.62%. Given Xencor's higher possible upside, analysts clearly believe Xencor is more favorable than Mirum Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mirum Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
2 Strong Buy rating(s)
3.17
Xencor
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.89

Xencor has lower revenue, but higher earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mirum Pharmaceuticals$379.25M5.75-$163.41M-$1.61-27.36
Xencor$127.23M4.30-$126.09M-$3.06-2.51

In the previous week, Mirum Pharmaceuticals had 14 more articles in the media than Xencor. MarketBeat recorded 20 mentions for Mirum Pharmaceuticals and 6 mentions for Xencor. Mirum Pharmaceuticals' average media sentiment score of 1.34 beat Xencor's score of 1.17 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mirum Pharmaceuticals
11 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Xencor
4 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Mirum Pharmaceuticals beats Xencor on 11 of the 17 factors compared between the two stocks.

Get Xencor News Delivered to You Automatically

Sign up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XNCR vs. The Competition

MetricXencorPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$547.31M$6.51B$5.35B$8.44B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio-2.409.1526.9119.77
Price / Sales4.29259.30390.06119.10
Price / CashN/A65.8538.2534.62
Price / Book0.706.476.794.52
Net Income-$126.09M$144.21M$3.23B$248.23M
7 Day Performance-6.49%2.64%1.99%0.77%
1 Month Performance-28.00%4.80%11.45%13.45%
1 Year Performance-68.70%-2.52%17.35%7.67%

Xencor Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
XNCR
Xencor
3.8594 of 5 stars
$7.69
+2.3%
$29.50
+283.6%
-68.6%$547.31M$127.23M-2.40280
MIRM
Mirum Pharmaceuticals
4.0712 of 5 stars
$44.89
-0.3%
$60.73
+35.3%
+68.0%$2.22B$379.25M-22.22140News Coverage
Positive News
Analyst Forecast
Analyst Revision
APLS
Apellis Pharmaceuticals
4.2008 of 5 stars
$17.67
+1.3%
$40.42
+128.8%
-59.2%$2.22B$775.84M-8.70770Analyst Forecast
Gap Up
ARWR
Arrowhead Pharmaceuticals
3.517 of 5 stars
$15.74
+0.2%
$42.13
+167.6%
-38.8%$2.17B$545.21M-3.04400News Coverage
Analyst Forecast
Analyst Revision
VCEL
Vericel
2.6795 of 5 stars
$42.54
+0.1%
$60.86
+43.1%
-17.8%$2.14B$238.54M709.12300News Coverage
Positive News
Analyst Forecast
NAMS
NewAmsterdam Pharma
2.6685 of 5 stars
$19.03
+0.8%
$43.00
+126.0%
-6.6%$2.09B$47.14M-10.124Positive News
Analyst Downgrade
GMTX
Gemini Therapeutics
N/A$48.09
+2.1%
N/A+56.4%$2.08BN/A-48.0930High Trading Volume
AAPG
Ascentage Pharma Group International
N/A$23.78
+5.0%
N/AN/A$2.07B$980.65M0.00600News Coverage
Positive News
Gap Down
BLTE
Belite Bio
2.0404 of 5 stars
$65.00
+0.9%
$96.67
+48.7%
+43.5%$2.07BN/A-58.5610News Coverage
Analyst Downgrade
Analyst Revision
HRMY
Harmony Biosciences
4.7845 of 5 stars
$35.91
+2.4%
$52.78
+47.0%
+13.1%$2.06B$744.85M17.02200Positive News
DNLI
Denali Therapeutics
4.4937 of 5 stars
$13.91
+0.9%
$33.71
+142.4%
-31.9%$2.02B$330.53M-5.04430Gap Down

Related Companies and Tools


This page (NASDAQ:XNCR) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners